Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JULIO C CHAVEZ

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1750543948
CMS profile
1011346
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$100,145.87

68 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $31,502.39 20
Genmab U.S., Inc. $23,540.83 14
ABBVIE INC. $22,847.67 14
Kite Pharma, Inc. $11,803.89 7
E.R. Squibb & Sons, L.L.C. $9,072.50 1
Celgene Corporation $1,132.08 10
AstraZeneca Pharmaceuticals LP $135.26 1
Novartis Pharmaceuticals Corporation $111.25 1

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JULIO C CHAVEZ

NPI 1750543948 · CMS profile ID 1011346

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750543948?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JULIO C CHAVEZ, NPI 1750543948, CMS profile ID 1011346. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750543948?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JULIO C CHAVEZ, NPI 1750543948, CMS profile ID 1011346. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750543948?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JULIO C CHAVEZ, NPI 1750543948, CMS profile ID 1011346, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1750543948?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

68 matching records · $100,145.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 68 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–68 of 68.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $111.2504/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200005506 CMS
ABBVIE INC. $362.5004/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201640461 CMS
ABBVIE INC. $99.5704/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201640457 CMS
ABBVIE INC. $474.8104/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201640459 CMS
ABBVIE INC. $5,075.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201640455 CMS
ABBVIE INC. $125.0003/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201640451 CMS
ABBVIE INC. $998.7603/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201640453 CMS
Genmab U.S., Inc. $5,075.0003/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1235921194 CMS
Genmab U.S., Inc. $791.9002/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235921196 CMS
Genmab U.S., Inc. $121.8402/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235921198 CMS
Lilly USA, LLC $3,200.0002/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186685817 CMS
Lilly USA, LLC $2,800.0002/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186685819 CMS
Lilly USA, LLC $541.6702/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186685815 CMS
Lilly USA, LLC $386.0802/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186736743 CMS
Lilly USA, LLC $163.8502/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186748409 CMS
Lilly USA, LLC $158.7302/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186748411 CMS
ABBVIE INC. $362.5001/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201640449 CMS
Lilly USA, LLC $1,600.0001/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186666909 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $58,688.16 47
PY2020 $48,990.40 27
PY2021 $29,930.50 28
PY2022 $34,392.14 34
PY2023 $60,194.18 52
PY2024 $50,500.01 46
PY2025 $100,145.87 68

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,911.43 6
PY2025 Principal investigator $2,746,782.29 130
PY2024 Recipient $2,408.08 7
PY2024 Principal investigator $2,404,588.27 146
PY2023 Recipient $8,104.48 3
PY2023 Principal investigator $1,978,343.29 113
PY2022 Recipient $3,786.08 1
PY2022 Principal investigator $1,876,549.98 128
PY2021 Recipient $370.58 2
PY2021 Principal investigator $1,834,517.85 196
PY2020 Recipient $2,475.00 1
PY2020 Principal investigator $2,938,832.81 108
PY2019 Recipient $1,469.41 7
PY2019 Principal investigator $2,239,215.60 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

136 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Hoffmann-La Roche Limited $84,188.94 12/24/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550391
Principal investigator 1 Genentech, Inc. $258.00 12/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550591
Principal investigator 1 Hoffmann-La Roche Limited $39,644.00 12/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550395
Recipient F. Hoffmann-La Roche AG $1,051.67 12/12/2025 Covered Recipient Physician Baseline characteristics and outcomes for large B-cell lymphoma (LBCL) patients previously treated with gemcitabine-oxaliplatin plus rituximab (R-GemOx) and subsequently enrolled in clinical trials GO40516 or GO29781 in the United States (US) No dispute reported 06/30/2026 1211536961
Recipient F. Hoffmann-La Roche AG $616.07 12/12/2025 Covered Recipient Physician Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211536964
Principal investigator 1 BeOne Medicines Ltd. $67,072.00 12/10/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337657
Principal investigator 1 Epizyme, Inc. $83.33 12/10/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282235
Principal investigator 1 Epizyme, Inc. $85.84 12/10/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282237
Principal investigator 1 Epizyme, Inc. $258.00 12/10/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282239
Principal investigator 1 Epizyme, Inc. $774.00 12/10/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282243
Principal investigator 1 Epizyme, Inc. $1,500.00 12/10/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282247
Principal investigator 1 Epizyme, Inc. $1,536.00 12/10/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282249
Principal investigator 1 Epizyme, Inc. $2,627.00 12/10/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282251
Recipient F. Hoffmann-La Roche AG $460.12 12/10/2025 Covered Recipient Physician Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211536972
Principal investigator 1 Genentech, Inc. $258.00 12/10/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550593
Principal investigator 1 Genentech, Inc. $68.00 12/10/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550597
Recipient F. Hoffmann-La Roche AG $440.24 12/08/2025 Covered Recipient Physician Baseline characteristics and outcomes for large B-cell lymphoma (LBCL) patients previously treated with gemcitabine-oxaliplatin plus rituximab (R-GemOx) and subsequently enrolled in clinical trials GO40516 or GO29781 in the United States (US) No dispute reported 06/30/2026 1211536968
Principal investigator 1 Hoffmann-La Roche Limited $135,594.72 12/01/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550387
Principal investigator 1 Hoffmann-La Roche Limited $32,850.80 11/14/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550382
Principal investigator 1 BeOne Medicines Ltd. $67,072.00 11/10/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330649
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $24,347.88 11/07/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Anti-Lymphoma Agents in Subjects with Relapsed OR Refractory non-Hodgkin Lymphomas (R/R NHL). No dispute reported 06/30/2026 1236000586
Principal investigator 1 BeOne Medicines Ltd. $8,384.00 11/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337659
Principal investigator 1 BeOne Medicines Ltd. $25,152.00 11/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337663
Principal investigator 1 Genentech, Inc. $68.00 11/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550577
Principal investigator 1 Genentech, Inc. $4,848.00 11/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550581
Principal investigator 1 Genentech, Inc. $3,000.00 11/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550584
Principal investigator 1 Genentech, Inc. $1,391.00 11/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550587
Principal investigator 1 Hoffmann-La Roche Limited $678.00 11/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550374
Principal investigator 1 Hoffmann-La Roche Limited $13,923.00 11/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550378
Principal investigator 1 Epizyme, Inc. $916.63 10/31/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282245
Principal investigator 1 BeOne Medicines USA, Inc. $12,654.54 10/28/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190333141
Principal investigator 1 Hoffmann-La Roche Limited $98,867.14 10/15/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550355
Principal investigator 1 Hoffmann-La Roche Limited $99,030.34 10/15/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550359
Principal investigator 1 Hoffmann-La Roche Limited $21,587.56 10/15/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550366
Principal investigator 1 Hoffmann-La Roche Limited $816.00 10/15/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550370
Principal investigator 1 Genmab U.S., Inc. $420.00 10/14/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235930250
Principal investigator 1 Genmab U.S., Inc. $402.90 10/14/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235930264
Principal investigator 1 Epizyme, Inc. $429.20 10/10/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282241
Principal investigator 1 Genmab U.S., Inc. $1,424.00 10/09/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235930247
Recipient Novartis Pharmaceuticals Corporation $115.00 10/09/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291872
Principal investigator 1 Hoffmann-La Roche Limited $266.00 10/08/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550348
Principal investigator 1 Hoffmann-La Roche Limited $266.00 10/08/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550362
Principal investigator 1 BeOne Medicines USA, Inc. $32,501.81 10/07/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190333137
Principal investigator 1 Hoffmann-La Roche Limited $1,060.00 10/01/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550350
Principal investigator 1 Genmab U.S., Inc. $130.56 09/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925948
Principal investigator 1 Genentech, Inc. $1,071.00 09/11/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550561
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,005.00 09/02/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma No dispute reported 06/30/2026 1190301189
Principal investigator 1 Epizyme, Inc. $1,001.00 08/28/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282867
Principal investigator 1 Celgene Corporation $104,895.82 08/27/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222305376
Principal investigator 1 Genmab U.S., Inc. $7,686.72 08/27/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925960
Principal investigator 1 Hoffmann-La Roche Limited $21,021.00 08/27/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550334
Principal investigator 1 Hoffmann-La Roche Limited $707.00 08/27/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550337
Principal investigator 1 BeOne Medicines USA, Inc. $140,587.41 08/26/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190333134
Principal investigator 1 Genmab U.S., Inc. $4,169.76 08/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925945
Principal investigator 1 Genmab U.S., Inc. $119,090.10 08/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925956
Principal investigator 1 Novartis Pharmaceuticals Corporation $111,403.20 08/14/2025 Non-covered Recipient Entity
MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL No dispute reported 06/30/2026 1190309562
Principal investigator 1 BeOne Medicines USA, Inc. $369.00 08/12/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332349
Principal investigator 1 Genentech, Inc. $136.00 08/01/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550565
Principal investigator 1 Genentech, Inc. $258.00 08/01/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550568
Principal investigator 1 Genentech, Inc. $516.00 08/01/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550572
Principal investigator 1 Epizyme, Inc. $958.80 07/30/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282865
Principal investigator 1 Hoffmann-La Roche Limited $266.00 07/30/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550344
Principal investigator 1 BeOne Medicines USA, Inc. $460.00 07/29/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332343
Principal investigator 1 Genmab U.S., Inc. $266.00 07/29/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925941
Principal investigator 1 Novartis Pharmaceuticals Corporation $421.62 07/28/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL No dispute reported 06/30/2026 1190301203
Principal investigator 1 Genmab U.S., Inc. $19,216.80 07/25/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925952
Principal investigator 1 BeOne Medicines USA, Inc. $1,000.00 07/22/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332339
Principal investigator 1 BeOne Medicines USA, Inc. $2,762.00 07/22/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332341
Principal investigator 1 BeOne Medicines Ltd. $67,072.00 07/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337749
Principal investigator 1 BeOne Medicines USA, Inc. $29,785.21 07/15/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190333129
Principal investigator 1 BeOne Medicines USA, Inc. $11,072.00 07/07/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332345
Principal investigator 1 BeOne Medicines USA, Inc. $369.00 07/07/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332347
Principal investigator 1 Hoffmann-La Roche Limited $3,000.00 07/02/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550341
Principal investigator 1 Genmab U.S., Inc. $64,340.24 06/24/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925916
Principal investigator 1 Epizyme, Inc. $258.00 06/23/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282863
Principal investigator 1 Genentech, Inc. $258.00 06/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550510
Principal investigator 1 Genentech, Inc. $136.00 06/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550514
Principal investigator 1 Genentech, Inc. $516.00 06/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550525
Principal investigator 1 Genentech, Inc. $516.00 06/18/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550549
Principal investigator 1 BeOne Medicines USA, Inc. $13,678.74 06/17/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190326716
Principal investigator 1 Genentech, Inc. $136.00 06/13/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550534
Principal investigator 1 Genmab U.S., Inc. $321,923.06 06/13/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925933
Principal investigator 1 BeOne Medicines Ltd. $67,072.00 06/11/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190342701
Principal investigator 1 Genmab U.S., Inc. $266.00 06/05/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925924
Principal investigator 1 Genentech, Inc. $774.00 06/04/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550506
Principal investigator 1 Genentech, Inc. $516.00 06/04/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550528
Principal investigator 1 Genentech, Inc. $258.00 06/04/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550542
Principal investigator 1 Genentech, Inc. $258.00 06/04/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550553
Principal investigator 1 BeOne Medicines USA, Inc. $20,799.42 05/30/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190326718
Principal investigator 1 Genmab U.S., Inc. $204.00 05/28/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925912
Principal investigator 1 Genentech, Inc. $516.00 05/23/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550502
Principal investigator 1 Genentech, Inc. $516.00 05/23/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550517
Principal investigator 1 Genentech, Inc. $1,032.00 05/23/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550521
Principal investigator 1 Genentech, Inc. $516.00 05/23/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550538
Principal investigator 1 Genentech, Inc. $516.00 05/23/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550545
Principal investigator 1 Genmab U.S., Inc. $266.00 05/22/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925905
Principal investigator 1 Celgene Corporation $71,268.76 05/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222305336
Principal investigator 1 Hoffmann-La Roche Limited $3,865.00 05/14/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550330
Principal investigator 1 BeOne Medicines USA, Inc. $73,461.00 05/12/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190326720
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,603.50 05/09/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma No dispute reported 06/30/2026 1190296547
Principal investigator 1 Genmab U.S., Inc. $420.00 05/08/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925909
Principal investigator 1 Genmab U.S., Inc. $25,943.36 05/08/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925920
Principal investigator 1 Celgene Corporation $42,184.00 05/02/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222304583
Principal investigator 1 Genmab U.S., Inc. $204.00 04/24/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925937
Principal investigator 1 BeiGene, Ltd. $75,456.00 04/09/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190324096
Principal investigator 1 Genentech, Inc. $4,540.77 04/09/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550557
Principal investigator 1 BeiGene, Ltd. $25,152.00 04/07/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190325464
Principal investigator 1 Genmab U.S., Inc. $266.00 04/04/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925929
Principal investigator 1 Genentech, Inc. $24,301.15 03/26/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 No dispute reported 06/30/2026 1211550498
Principal investigator 1 Genmab U.S., Inc. $266.00 03/13/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925895
Principal investigator 1 Hoffmann-La Roche Limited $44,039.00 03/12/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL No dispute reported 06/30/2026 1211550325
Principal investigator 1 Kite Pharma, Inc. $4,950.00 03/11/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067528
Principal investigator 1 Kite Pharma, Inc. $8,190.00 03/11/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067531
Principal investigator 1 Epizyme, Inc. $258.00 03/04/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282861
Principal investigator 1 Genmab U.S., Inc. $204.00 02/27/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925888
Principal investigator 1 Epizyme, Inc. $1,400.80 02/13/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282859
Principal investigator 1 Genmab U.S., Inc. $266.00 02/13/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925882
Principal investigator 1 Genmab U.S., Inc. $382.16 02/13/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925885
Principal investigator 1 Kite Pharma, Inc. $995.00 02/11/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067515
Principal investigator 1 Kite Pharma, Inc. $250.00 02/11/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067521
Principal investigator 1 Genmab U.S., Inc. $204.00 02/06/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925891
Principal investigator 1 Genmab U.S., Inc. $14,727.10 02/06/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925902
Principal investigator 1 Novartis Pharmaceuticals Corporation $371,425.00 02/04/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL No dispute reported 06/30/2026 1190295735
Principal investigator 1 Epizyme, Inc. $431.00 01/29/2025 Non-covered Recipient Entity
Moffitt Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282857
Principal investigator 1 Kite Pharma, Inc. $250.00 01/28/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067508
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,255.24 01/27/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL No dispute reported 06/30/2026 1190306227
Principal investigator 1 Kite Pharma, Inc. $867.68 01/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067480
Principal investigator 1 Kite Pharma, Inc. $0.20 01/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067487
Principal investigator 1 Kite Pharma, Inc. $0.40 01/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067493
Principal investigator 1 Kite Pharma, Inc. $204.00 01/21/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067502
Principal investigator 1 Genmab U.S., Inc. $207.06 01/16/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. No dispute reported 06/30/2026 1235925898
Recipient Novartis Pharmaceuticals Corporation $7,228.33 01/15/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293666
Principal investigator 1 Novartis Pharmaceuticals Corporation $96.02 01/15/2025 Non-covered Recipient Entity
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma No dispute reported 06/30/2026 1190306221
Principal investigator 1 Kite Pharma, Inc. $250.00 01/14/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067461
Principal investigator 1 Kite Pharma, Inc. $250.00 01/14/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067467
Principal investigator 1 Kite Pharma, Inc. $475.00 01/14/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212067474